AnalystBook Research · Company Intelligence

ALIGN TECHNOLOGY INC

ALGNNasdaq

Built from ALIGN TECHNOLOGY INC's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Align held revenue roughly flat, but earnings and FCF weakened.

The read at a glance✓ Audited against SEC data
  • Business mixClear Aligners; Systems & ServicesNote
  • Revenue$4.03B, +0.9%Note
  • Net income$410.4M, -2.6%Watch
  • FCF$490.8M, -21.2%Watch
  • MarginsGross/operating/FCF downWatch
  • Altman/Beneish/EQGrey Z; clean M/EQNote
  • Insiders2 purchases / 1 saleOK

Business

Align Technology sells Clear Aligner products and Systems and Services used in digital orthodontics and restorative dentistry.

Where the revenue comes from

Fiscal 2025, as ALIGN TECHNOLOGY INC reports it. History and quarterly detail are in the app.

  • Clear Aligner$3.2B
  • Systems and Services$789.6M

Leadership changes

From ALIGN TECHNOLOGY INC's own filings, the day they're filed.

  • Julie Coletti · Chief Legal Officer · departureeff. 2026-08-01
  • Kevin Conroy · Chairman · appointmenteff. 2026-07-01
  • Stuart Hockridge · President · departureeff. 2025-09-12

Latest filings

  • 8-K · Company announcement2026-08-31
  • 10-Q · Quarterly report2026-08-05
  • 8-K · Company announcement2026-07-29
  • 8-K · Company announcement2026-07-29
  • 8-K · Company announcement2026-07-09
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about ALIGN TECHNOLOGY INC, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.